TY  - JOUR
AU  - Besse, Benjamin
AU  - Lin, Jessica J
AU  - Bazhenova, Lyudmila
AU  - Goto, Koichi
AU  - de Langen, Adrianus Johannes
AU  - Kim, Dong-Wan
AU  - Wolf, Jürgen
AU  - Springfeld, Christoph
AU  - Popat, Sanjay
AU  - Lim, Darren W T
AU  - Nagasaka, Misako
AU  - Hong, Jung Yong
AU  - Baik, Christina S
AU  - Hervieu, Alice
AU  - Moreno, Victor
AU  - Yang, Nong
AU  - Kollengode, Kanthi
AU  - Yang, Haisu
AU  - Xu, Yuanfang
AU  - Calvet, Christophe Y
AU  - Yuan, Yong
AU  - Hammell, Amy B
AU  - Drilon, Alexander
AU  - Solomon, Benjamin J
TI  - Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trial.
JO  - Nature medicine
VL  - nn
SN  - 1078-8956
CY  - [New York, NY]
PB  - Springer Nature
M1  - DKFZ-2026-00289
SP  - nn
PY  - 2026
N1  - #NCTZFB9# / epub
AB  - Early-generation TRK tyrosine kinase inhibitors (TKIs) approved for treating NTRK fusion-positive (NTRK+) solid tumors provide clinical benefit; however, resistance emerges. Repotrectinib is a next-generation ROS1/TRK TKI with a compact macrocyclic structure designed to improve durability of response. TRIDENT-1 is a registrational phase 1/2 trial assessing repotrectinib, a next-generation ROS1/TRK TKI, in adults with advanced solid tumors, including NTRK+ disease. The primary endpoint was confirmed objective response; secondary endpoints included duration of response (DOR), progression-free survival (PFS), overall survival and safety. Median follow-up ranged between 21.3 months and 25.7 months. In the TKI-naive cohort (n = 51; 95
LB  - PUB:(DE-HGF)16
C6  - pmid:41639379
DO  - DOI:10.1038/s41591-025-04079-7
UR  - https://inrepo02.dkfz.de/record/309657
ER  -